General Information of Drug (ID: DMBPUIK)

Drug Name
BXCL701 Drug Info
Indication
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMBPUIK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Talabostat DM1IZ5D Constitutional neutropenia 4B00.0 Phase 3 [3]
Thiomorpholine derivative 1 DMZP6KR N. A. N. A. Patented [4]
Thiomorpholine derivative 2 DMWOK1D N. A. N. A. Patented [4]
PMID20684603C24dd DMWZK9U Discovery agent N.A. Investigative [5]
1G244 DMEB8CG Discovery agent N.A. Investigative [6]
PMID15664838C18 DM93RKC Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 6 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Talabostat DM1IZ5D Constitutional neutropenia 4B00.0 Phase 3 [3]
Thiomorpholine derivative 1 DMZP6KR N. A. N. A. Patented [4]
Thiomorpholine derivative 2 DMWOK1D N. A. N. A. Patented [4]
PMID20684603C24dd DMWZK9U Discovery agent N.A. Investigative [5]
1G244 DMEB8CG Discovery agent N.A. Investigative [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dipeptidyl peptidase 8 (DPP-8) TTJGLZF DPP8_HUMAN Inhibitor [2]
Dipeptidyl peptidase 9 (DPP-9) TTNDUL7 DPP9_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03910660) Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. U.S.National Institutes of Health.
2 DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma. J Immunother Cancer. 2021 Nov;9(11):e002837.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
5 Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors. J Med Chem. 2010 Aug 12;53(15):5620-8.
6 Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitor. Biochem Pharmacol. 2009 Jul 15;78(2):203-10.
7 Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8. Bioorg Med Chem Lett. 2005 Feb 1;15(3):687-91.